Get the Stockscreener App
5.12
2.48%
-0.13
Enanta Pharmaceuticals Inc stock is traded at $5.12, with a volume of 440.19K.
It is down -2.48% in the last 24 hours and down -18.47% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$5.25
Open:
$5.3
24h Volume:
440.19K
Relative Volume:
1.11
Market Cap:
$108.51M
Revenue:
$73.62M
Net Income/Loss:
$-138.24M
P/E Ratio:
-0.7805
EPS:
-6.56
Net Cash Flow:
$-99.19M
1W Performance:
+5.79%
1M Performance:
-18.47%
6M Performance:
-64.25%
1Y Performance:
-56.28%
1-Day Range:
$5.02
$5.3298
1-Week Range:
$4.71
$5.3298
52-Week Range:
$4.71
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
500 ARSENAL STREET, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
5.12 | 108.51M | 73.62M | -138.24M | -99.19M | -6.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
JPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Barclays PLC - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Brokerages - MarketBeat
Enanta stock hits 52-week low at $4.83 amid market challenges - Investing.com Nigeria
Enanta stock hits 52-week low at $4.83 amid market challenges By Investing.com - Investing.com South Africa
Jane Street Group LLC Has $240,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
ENTA (Enanta Pharmaceuticals) Peter Lynch Fair Value : N/A (As of Jan. 11, 2025) - GuruFocus.com
Enanta stock hits 52-week low at $5.29 amid market challenges - Investing.com Nigeria
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Has $4.95 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
(ENTA) Technical Pivots with Risk Controls - Stock Traders Daily
Enanta stock touches 52-week low at $5.68 amid market challenges - Investing.com Australia
Enanta stock touches 52-week low at $5.68 amid market challenges By Investing.com - Investing.com South Africa
Brokers Issue Forecasts for ENTA Q1 Earnings - Defense World
Equities Analysts Offer Predictions for ENTA Q1 Earnings - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
FY2029 Earnings Estimate for ENTA Issued By HC Wainwright - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Equities Analysts Set Expectations for ENTA FY2029 Earnings - MarketBeat
Pfizer prevails in Enanta patent case over Covid-19 drug By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals stock remains Buy-rated with Phase 2 data driving model revisions - Investing.com Australia
When (ENTA) Moves Investors should Listen - Stock Traders Daily
Pfizer prevails in Enanta patent case over Covid-19 drug - Investing.com India
Pfizer Gets Enanta Patent Voided in Case Over Paxlovid Royalties - Bloomberg Law
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dis - GuruFocus.com
HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00 - MarketBeat
Enanta to appeal as Pfizer wins Paxlovid patent ruling - MSN
Enanta stock slips as Pfizer wins Paxlovid patent (PFE:NYSE) - Seeking Alpha
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer - MarketWatch
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Enanta Loses Key Patent Battle Against Pfizer Over COVID Drug Paxlovid in Court Ruling - StockTitan
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com
(ENTA) Technical Data - Stock Traders Daily
Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada
FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):